In the past years, the canonical Wnt/β-catenin signaling pathway has emerged as a critical regulator of cartilage development and homeostasis. In this pathway, glycogen synthase kinase-3β (GSK3β) down-regulates transduction of the canonical Wnt signal by promoting degradation of β-catenin. In this study we wanted to further investigate the role of Gsk3β in cartilage maintenance. Therefore, we have treated chondrocytes ex vivo and in vivo with GIN, a selective GSK3β inhibitor.
Inhibition of Gsk3β in cartilage induces osteoarthritic features through activation of the canonical Wnt signaling pathway INTRODUCTION Differentiated chondrocytes maintain their phenotype via synthesis of cartilagespecific extracellular matrix (ECM) molecules including collagen type II and sulfated proteoglycans, like aggrecan (1) . Chondrocytes easily lose essential characteristics when they are removed from their natural environment and cultured in vitro or expanded for the purpose of cartilage tissue engineering (1;2) . Chondrocyte dedifferentiation also occurs in the presence of retinoic acid, nitric oxide, or proinflammatory cytokines like interleukin (IL)-1β and TNF-α, as well as in osteoarthritis (OA) (2) .
We and others have shown that both constitutive up-or down-regulation of the canonical Wnt pathway negatively influences cartilage development and maintenance resulting in OA-like features. This suggests that a tight regulation of this signaling cascade is crucial throughout the chondrocyte life-cycle (3) (4) (5) (6) . In this pathway, in the absence of a Wnt signal, a destruction complex comprising Axin (Conductin) and Adenomatous polyposis coli (APC) mediates the phosphorylation of β-catenin by GSK3β, which induces degradation of cytosolic β-catenin in the proteasome. Binding of Wnt to its transmembrane receptor Frizzled results in activation of Dishevelled. This is followed by reduction of GSK3β activity and accumulation of cytoplasmic β-catenin. Upon its nuclear translocation, β-catenin will function as a co-factor of TCF/LEF transcription factors to induce expression of Wnt target genes (6) . GSK3β is constitutively active and, unlike many kinases that are activated following stimulus-dependent phosphorylation, it becomes inactive following phosphorylation (7) . Studies reported so far indicate that Gsk3β activity is required for both chondrocyte and osteoblast differentiation and thus for endochondral bone development (8) . However, no data is available regarding the role of GSK3β in maintenance of the chondrocytic phenotype.
To better understand the role of Gsk3β in regulation of the chondrocyte life cycle, we inactivated this kinase ex vivo and in vivo by using 3-[9-Fluoro-2-(piperidine-1carbonyl)-1,2,3,4-tetrahydro- [1, 4] diazepino[6,7,1-hi]indol-7-yl]-4-imidazo[1,2-a]pyridin-3-yl-pyrrole-2,5-dione, a selective and potent GSK3β inhibitor, in this manuscript further referred to as GIN (9) . Our results imply that Gsk3β activity is crucial for maintenance of the chondrocytic phenotype and for the integrity of cartilage ECM, mainly by down-regulating the canonical Wnt signaling pathway. The cartilage phenotypic changes induced by GIN bear similarities to some of the clinical features commonly observed in OA.
MATERIALS AND METHODS
KS483 cell culture, immunofluorescence for β-catenin, transient transfection assays
Routine culture of KS483 cells in T75 culture flasks (Greiner Bio-One), immunofluorescence for β-catenin and transient transfection assays were performed as previously described (10) .
Ex vivo experiments
The three middle metatarsals were dissected from E17.5 Swiss Albino mouse embryos. Explants isolated from different animals were randomly distributed and individually cultured in 500 µl α-MEM (Invitrogen) medium containing 10% FCS (Invitrogen), 100 U Pen/Strep (Invitrogen) and 1% GlutaMax (Invitrogen). After an equilibration period of 48 hours, metatarsals were challenged with vehicle or GIN as described in the results section. All ex vivo experiments were approved by the ethical committee of the Leiden University Medical Center and complied with national laws relating to the conduct of animal experiments.
Proliferation and apoptosis assays
Chondrocyte proliferation was assessed by immunohistochemistry (IHC) for proliferating cell nuclear antigen (PCNA) according to manufacturer's protocol (Santa Cruz Biotechnology). Chondrocyte apoptosis was determined by the TUNEL reaction (Promega), as previously described (11) . For statistical analysis a number of N = 3 independent samples were used and each experiment was repeated at least once.
Histology, Immunohistochemistry, In situ hybridization
Histology, IHC, and in situ hybridization (ISH) were performed as previously described (5) .
Quantification of glycosaminoglycans
The glycosaminoglycan (GAG) content in N = 3 whole metatarsals per condition was quantified related to the amount of DNA using the Blyscan Sulfated GAG Assay kit (Biocolor) according to manufacturer's protocol. Experiments were repeated at least once.
Gene expression profiling
For each condition, RNA was isolated from N = 15 whole metatarsals, checked for quality, amplified and labeled as previously described (12) . Labeled cRNA was further used for the hybridization to Affymetrix GeneChip ® Mouse Genome 430A 2.0 Array according to the manufacturer's protocol. The raw and normalized data are deposited on the website of the Department of Tissue Regeneration of the Twente University Institute for Biomedical Technology (http://tr.tnw.utwente.nl).
Microarray data analysis
To evaluate the large number of genes and to find gene expression trends and noteworthy signaling pathways that are involved in the GIN-mediated effects, we used principal component analysis (13) . Using a cut-off value of 2 for the expression fold change, a list of 316 differentially expressed genes (225 down-and 91 up-regulated) was generated and used for subsequent analysis ( Table 1 and 2).
Functional annotation of the differentially expressed genes identified by the PCA analysis was performed using the DAVID bioinformatics database and the Gene Ontology (GO) terms to describe their (extra)cellular location (GO_CC), molecular functions (GO_MF), and the biological processes (GO_BP) in which they are involved (14) (15) (16) . Enrichment of GO functional groups was determined to be meaningful when the number of probe sets in our list that mapped to a specific GO term was greater than 2 with a p-value ≤ 0.001.
Validation of the microarray analysis was performed by real-time quantitative PCR as previously described (12) .
In vivo experiments
All in vivo experiments were approved by the ethical committee of the Erasmus University Medical Center and complied with national laws relating to the conduct of animal experiments. Thirteen-week-old male Wistar rats (400-450 g) were housed under standard laboratory conditions (temperature 24°C, 12-hour light-dark cycle) with food and water ad libitum. The animals were acclimatized to the laboratory environment for 3 weeks before the start of the experiments.
GIN treatment
In a dose-finding study (n=4), the effect of an intra-articular injection of 100 μl GIN dissolved in PBS at concentrations of 3*10 -7 M, 10 -6 M, 3*10 -6 M, and 10 -5 M in the knee joint was investigated.
In a second experiment, 8 rats were injected intra-articularly at day 1, 3 and 5 with 100 μl 10 -5 M GIN. Four rats were injected with GIN in the left knee, the remaining 4 were injected in the right knee. Contralateral joints served as controls and were injected with vehicle. All animals were scanned using contrast-enhanced microCT (CECT) before GIN injection (t = 0) and during follow up as previously described (17) . Rats were sacrificed at the times indicated in the text.
Microscopical analysis and quantification
IHC for β-catenin coupled with Alcian Blue (AB) counterstaining for GAGs was carried out as previously described (5) . Quantification of the AB staining was performed using Image-Pro Plus software, version 7.0.
Statistical analysis
All values represent median and range for experiments when N ≤ 4 and mean and 95% confidence interval (CI) when N ≥ 5. The paired t-test, the univariate general linear model using simple contrasts and parameter estimates and one-way ANOVA were used to assess the data, as appropriate. P values less than 0.05 were considered significant. Statistical analysis was performed using SPSS v16.0 (SPSS).
RESULTS

Inhibition of Gsk3β through GIN results in activation of the canonical Wnt signaling pathway in vitro and ex vivo
We first performed transient transfection experiments in mesenchymal-like KS483 cells using the Wnt-responsive BAT-Luc reporter vector (10;18). As expected, GIN induced a dose-dependent increase in luciferase activity, with a maximum response at 10 -7 M ( Figure 1A ). At higher concentrations, the luciferase activity decreased, presumably due to toxic effects ( Figure 1A and data not shown). Furthermore, GIN was significantly more potent in inducing the Wnt reporter construct than LiCl, another established inhibitor of GSK3β. Activation of the Wnt reporter construct by 10 -7 M GIN was accompanied by β-catenin accumulation and nuclear translocation as confirmed by immunofluorescence ( Figure 1B ). The overall level of β-catenin was notably increased in cells treated with GIN when compared to LiCl (50 mM) or Wnt3a (50 ng/ml) ( Figure  1B ).
We next investigated the effect of GIN on fetal mouse metatarsals, which represent an established model for studying the chondrocyte life cycle ex vivo (19) . After incubation for 3 days, GIN dose-dependently increased the levels of β-catenin as revealed by IHC ( Figure 1C ). Metatarsals treated with either 10 -7 M or 10 -6 M GIN displayed β-catenin staining mainly in the nuclei, indicating an efficient activation of the canonical Wnt signal. The latter concentration resulted in immunohistochemically detectable nuclear β-catenin expression in almost all chondrocytes. Strikingly, metatarsals treated with 10 -6 M GIN displayed a much fainter AB counterstaining in comparison to controls, indicative for loss of GAGs. Additional morphological analysis revealed no evidence of cell death, cell shrinkage, picnotic nuclei, blebbing of the cytoplasm or necrosis. Subsequent experiments using the fetal mouse metatarsal ex vivo culture model were performed with 10 -6 M GIN.
GIN inhibits chondrocyte proliferation and increases cartilage apoptosis
We assessed the effect of GIN on chondrocyte proliferation using IHC for PCNA. The percentage of proliferating cells was smaller in the GIN-treated group compared to controls at all time points examined (Figure 2A -E). Chondrocyte proliferation was significantly inhibited both at d1 (11.3% vs. 25.9%, p = 0.048) and at d3 (7.6% vs. 27.8%, p = 0.014). TUNEL staining in combination with histological evaluation was used to assess chondrocyte apoptosis. GIN did not have an effect on TUNEL positivity at 6h, d1 and d3 ( Figure 2F -J). Only after prolonged GIN treatment (d7), TUNEL staining was significantly increased (22.9% vs. 6.0%, p = 0.043). At d7, TUNEL-positive cells were predominantly identified among the hypertrophic chondrocytes in controls. In contrast, TUNELpositive cells were also observed among the resting and proliferative chondrocytes in the GIN-treated group. Based on histological evaluation, TUNEL-positive cells underwent apoptosis.
Inhibition of Gsk3β induces degradation of cartilage matrix and loss of the chondrocytic phenotype ex vivo
We investigated the effect of GIN at the cellular level by IHC analysis for β-catenin, collagen type II and X, and ISH analysis for Col2a1 and Col10a1. No microscopical differences between vehicle-and GIN-treated metatarsals were observed at 6h (data not shown). B-catenin expression at the start of the experiment and in the control metatarsals at d1, d3 and d7 was restricted to the cytoplasm of a minority of perichondrial and periosteal cells ( Figure 3A , A i , A iii , A v ). We first noticed a clear increase in the level of nuclear β-catenin after 1 day of GIN treatment ( Figure 3A inversely correlated with the intensity of the AB counterstaining ( Figure 3A -A vi ). GIN treatment progressively decreased the GAG content in the ECM, with a near complete loss of GAGs at d7 ( Figure 3F ). GIN did not have an effect on mineral deposition and ossification of the metatarsals (data not shown).
Additional microscopical analysis revealed Col2a1 mRNA and collagen type II protein expression in the resting, proliferative and prehypertrophic chondrocytes, and their matrix, respectively, at all time points in the controls ( Figure 3B , B i , B iii , B v , C, C i , C iii , C v ). GIN treatment for 1 day resulted in a considerable inhibition of the mRNA expression of this chondrocyte marker, whereas its protein expression was not changed ( Figure 3B ii , C ii ). At d3, most of the chondrocytes in the GIN-treated metatarsals, although surrounded by a matrix rich in collagen type II, failed to express Col2a1 ( Figure  3B iv , C iv ). At d7, neither Col2a1 nor collagen type II expression was found in the GINtreated metatarsals ( Figure 3B vi , C vi ). Chondrocyte marker expression at the mRNA level is inhibited after 3-day-long GIN treatment. Chondrocytes exposed to GIN for 7 days fail to express specific markers at both mRNA and protein level. Scale bar: 100 μm. (F) Quantification of GAGs corrected for DNA (N = 3 independent samples) validates the microscopical findings. *p = 0.023 (d1), *p = 0.016 (d3), **p = 0.008 (d7), all GIN vs. same time point untreated. Data are expressed in arbritary GAG/DNA units (black triangles -controls, grey triangles -GIN treated samples).
Furthermore, control metatarsals displayed Col10a1 and collagen type X expression in the hypertrophic zone ( Figure 3D, D 
. At d1, there were no differences in the expression of this mature chondrocyte marker between the control and the GIN-treated group, neither at the mRNA nor at the protein level ( Figure 3D ii , E ii ). At d3, GIN-treated explants displayed no Col10a1 expression, whereas collagen type X was still present in the ECM ( Figure 3D iv , E iv ). Ultimately, at d7, GIN induced a complete absence of both Col10a1 and collagen type X ( Figure 3D vi , E vi ).
Microarray analysis confirms GIN's proteolytic effects on cartilage
To further examine the effects of GIN on gene expression patterns in the fetal mouse metatarsal model, we performed cDNA microarray analysis on mRNA isolated from GIN-treated and control explants at T0, 6h, d1 and d3. We particularly designed our microarray analysis as such since GIN-treated metatarsals at d7 showed only aggravated features of the ones observed at d3. Furthermore, the increased apoptosis at d7 would have jeopardized the specificity of the results and mainly revealed differentially expressed genes related to cell death, an indirect effect of GIN treatment.
According to GO_CC terms, the vast majority of the 316 differentially expressed genes (225 down-and 91 up-regulated) encoded proteins that are active in the ECM ( Figure 4A ). Classification according to GO_MF and GO_BP terms is represented in Figure 4B and 4C, respectively. The large number of up-regulated genes and the fact that they did not categorize under any GO terms related to cell death suggested that our microarray data efficiently revealed biological effects caused by GIN treatment and not by toxicity.
In consistence with the microscopical findings indicating significant cartilage matrix degradation, we found among the 91 up-regulated genes numerous transcripts encoding established proteinases: Matrix metallopeptidase 9 (Mmp9), Mmp10, Mmp11, and HtrA serine peptidase 1 (Htra1). Given the role of GSK3β in canonical Wnt signaling, the microarray data showed evidence for a Wnt/β-catenin signature as evidenced by the upregulation of established direct targets of the β-catenin/TCF4 complex, like Axin2 and adenomatosis polyposis coli down-regulated 1 (Apcdd1). Microarray and pathway analysis did not reveal clear signatures of changes in other signaling pathways, such as Hedgehog and FGF. Furthermore, several cartilage ECM proteins were identified among the 225 down-regulated genes: unique cartilage matrixassociated protein (Ucma), matrilin 1 (Matn1), Matn3, Matn4, hyaluronan and proteoglycan link protein 1 (Hapln1), collagen, type XI, alpha 1 (Col11a1), epiphycan (Epyc), fibromodulin (Fmod), matrix Gla protein (Mgp), Col14a1, and (Col9a3). In the list of repressed genes, we also found transcripts known to encode non-cartilaginous matrix proteins like osteomodulin (Omd), osteoglycin (Ogn), microfibrillar-associated protein 4 (Mfap4), tenomodulin (Tnmd), asporin (Aspn), and fibulin7 (Fbln7), suggesting a more complex effect of the GIN treatment on the extracellular matrix.
To independently validate the results of the microarray analysis, 16 genes were selected for confirmation by quantitative real-time RT-PCR analysis. For the transcriptional analysis we therefore isolated RNA from a separate experiment that mirrored the one used to generate the microarray data. Four of these 16 genes are known to be involved in chondrocyte differentiation and cartilage maintenance (Sox9, Col2a1, Acan and Col10a1), 4 are members of the canonical Wnt signaling pathway (Axin1, Axin2, Gsk3b and Ctnnb1), and 8 encode proteinases known to regulate maintenance and degradation of the ECM (Mmp2, Mmp3, Mmp9, Mmp13, Adamts4, Adamts5, Hyal1 and CtsK). We found a similar expression pattern of the analyzed genes, indicating that our microarray data specifically corresponded to actual gene expression patterns ( Figure 5 ). 
GIN induces OA-like effects in vivo
We next investigated whether GIN can induce the same biological effects in an in vivo experimental model. In an initial experiment, we observed 72 hours after GIN injection nuclear translocation of β-catenin in a dose-dependent fashion in rat knee articular chondrocytes, whereas vehicle treatment did not induce a change in β-catenin expression in the control joints ( Figure 6A, A i , B , B i and data not shown). Virtually all articular chondrocytes treated with the highest GIN concentration (10 -5 M) showed nuclear β-catenin expression, yet they did not display any morphological changes or alterations of their ECM. We did not detect β-catenin up-regulation in other tissues such as synovium, tendons, or bone at the examined time point, nor evidence of inflammation. In a second experiment, we injected 10 -5 M GIN on day 1, 3 and 5. Four rats ("early" group) displayed signs of severe acute inflammation of the GIN-treated knee beginning at day 7 and these animals were therefore sacrificed already at day 10. No difference in β-catenin expression was observed between the GIN-treated and control knees of these animals (data not shown). In the vehicle-injected knee, the surface of the AC was smooth, the matrix was densely stained with AB and showed no signs of degeneration ( Figure 6C , C i ). Besides displaying histological signs of inflammation (intra-articular infiltration of neutrophils and macrophages, synoviocyte hyperplasia, fibrin exudation etc.), the GIN-treated knees in the "early" group displayed intensely degraded AC, containing almost no GAGs, as indicated by absence of AB staining (Figure 6D , D i and data not shown) in each of the 4 animals.
The other 4 rats ("late" group) from this experiment were sacrificed after 6 weeks and again showed no difference in the β-catenin expression pattern between the GINtreated knee and controls ( Figure 6E , E i , F, F i ). Whereas no morphological changes were observed in the control knees of the "late" group, GIN-treated samples from all 4 rats displayed superficial fibrillation of AC, focal hypocellularity of chondrocytes, and reduced AB staining. Quantification of the intensity of the AB staining revealed significantly less staining in the cartilage of GIN-treated knees in comparison to contralateral control knees ( Figure 6G, p=0.05) .
Although not statistically significant, CECT analysis of condylar cartilage revealed a trend in reduction of cartilage volume as well as GAG-depletion (expressed by increased attenuation) in the GIN-treated knee joints in comparison to control knees ( Figure 6H, I) .
DISCUSSION
Here we show that Gsk3β, by controlling the canonical Wnt signaling pathway, is critical for maintenance of the chondrocytic phenotype. Inhibition of Gsk3β in chondrocytes ex vivo leads to loss of cartilage markers expression, induces matrix degradation by stimulating the expression of Mmps, inhibits chondrocyte proliferation and, most likely as a consequence of these effects, induces chondrocyte apoptosis. In addition, we demonstrate that transient inhibition of Gsk3β, following three intra-articular injections of GIN in rat knees during 1 week is associated with the appearance of OA-like features 6-weeks later. In agreement with our results, recent findings suggest that upregulation of β-catenin through induction of proteasomal degradation of Gsk3β in chondrocytes initiates early events of OA, while inhibition of Gsk3β may block chondrogenesis (20;21) .
Besides the canonical Wnt pathway, GSK3β also regulates signal transduction of the Hedgehog (Hh) and Fibroblast growth factor (Fgf) family of secreted proteins (22;23) . Given that both Hh and Fgf growth factors play important roles in the chondrocyte life cycle, we searched in our microarray results for possible target genes of these proteins among the list of transcripts differentially regulated by GIN (24; 25) . Only PR domain containing 1, with ZNF domain (Prdm1) matched this criterion, acting down-stream of a sequential Wnt and Fgf signaling cascade (26) . Our microarray expression data indicated that GIN treatment up-regulated the canonical Wnt target genes Axin2 and Apcdd1, transcripts that have previously been shown to be induced only by Wnt and not by Fgf signaling (27) (28) (29) . The protein products of Axin2 and Naked cuticle homolog 2, both of which are upregulated in the microarray, are both renowned antagonists of the canonical Wnt signal. They have been shown to participate in negative feedback regulation of β-catenin activity (30) (31) (32) . Taken together, these findings suggest that the intense cartilage matrix degeneration as well as the loss of the chondrocytic phenotype following GIN treatment occurred, at least in our experimental set-up, mainly due and can be explained by the activation of the Wnt/β-catenin pathway, although we cannot exclude minor roles of other signaling pathways in which GSK3β is known to be implicated nor of minor off-target effects of GIN.
Previously, we and others have reported that continuous exposure of chondrocytes to extensive levels of β-catenin in vivo induces loss of the chondrocytic phenotype as evidenced by the loss in expression of typical chondrocyte markers (5;6) . Microarray analysis of GIN-treated metatarsals confirmed and extended this observation. Furthermore, our microscopical analysis suggests that GIN not only induced an enhanced degradation of the ECM, but also inhibited the expression of several ECM constituents in a time-dependent manner. Noteworthy, in the metatarsal experiments the loss of expression of typical cartilage markers at the mRNA level was observed before protein degradation was noticeable. GIN treatment inhibited the expression of genes encoding collagenous (Col9a3, Col11a1, and Col14a1), and non-collagenous ECM proteins (Ucma, Matn1, Matn3, Matn4, Hapln1, Fmod, Mgp), as well as proteoglycans (Epyc). In addition, GIN stimulated the expression of proteinases Mmp9, Mmp10, Mmp11, and Htra1, which promote ECM degradation, suggesting that the loss of tissue integrity observed in the treated metatarsals is due not only to a loss of the links between the collagenous and the non-collagenous proteins in the matrix, but also to active matrix degradation.
Decreased chondrocyte proliferation, augmented apoptosis, loss of the chondrocytic phenotype and degradation of ECM together characterize the "degradative phase" of OA, the most common form of arthritis (33) . These pathological phenomena were observed after up-regulated canonical Wnt signaling by GIN-treatment in our experimental set-ups ex vivo and in vivo, in agreement with recent data suggesting a link between excess signaling through the Wnt/β-catenin pathway and OA (6) . Moreover, many genes reportedly induced in OA cartilage were up-regulated by GIN treatment: Mmp9, Mmp10, Mmp11, Axin2, Htra1, angiopoietin-like 2 (Angptl2), and met proto-oncogene (Met) (2; [34] [35] [36] [37] [38] . Htra1, which is increased several-fold in joint cartilage of OA patients, promotes degeneration of cartilage (36;39), while Met, besides contributing to the altered metabolism during OA, also stimulates osteophyte development (40) . Serping1, previously reported to be repressed in OA, and Matn3, whose inactivation leads to higher incidence of OA, were both down-regulated by GIN (41; 42) . In addition, inactivation of Frzb, another transcript repressed by GIN treatment, renders joints more susceptible for osteoarthritic changes (43) .
Our results suggest that treatment with GIN can induce cartilage degeneration of rat AC after 3 intra-articular injections of GIN with a two days interval. We observed two distinct phenotypes, most likely explained by a difference in retention time of GIN in the knee joint: a severe form with acute inflammation associated with resorption already 10 days after the first injection a milder phenotype. The potent catabolic effects of GIN on cartilage may have caused rapid and excessive cartilage degradation. These degradation products may have triggered an acute form of inflammation through the release of for example collagen type II fragments. In animals with the milder phenotype, microscopical analysis demonstrated the presence of the first signs of OA-like changes such as surface fibrillation, focal chondrocyte hypocellularity and a decrease in GAG staining in GIN-treated knees but not in the contralateral control knees 6-weeks after the last GIN-injection. CECT analysis revealed a trend of less cartilage volume and more attenuation, indicative for GAG loss in the GIN treated animals; however this observation did not reach significance. In contrast to the increased β-catenin expression in AC present 3 days after GIN injection, we did not detect increased β-catenin staining 6 weeks after GIN injection nor did we found evidence for nuclear β-catenin accumulation in the synovium, tendons or bone at each of the analysed time points. This suggests that a transient rise in β-catenin in AC may be sufficient to trigger development of OA-like features, an observation that extends findings in conditional constitutive mice carrying a stabilized, oncogenic variant of β-catenin, which also develop OA (4). Although we did not find evidence for increased β-catenin accumulation in other joint tissues besides cartilage at the examined time points, we cannot exclude that GINinjection has resulted in a more rapid and transient rise of β-catenin in these tissues which was normalized 72 hours after the injection. This may have also contributed to the observed pathology. Furthermore, we cannot exclude that the mild cartilage phenotype was due to a milder form of inflammation in the first weeks after injection. However, given the clear evidence of increased nuclear β-catenin accumulation in AC 72 hours after GIN injection and the consistency of the in vivo findings with the phenotypic changes and effects on gene expression of GIN in our ex vivo cartilage explant model, we favor the hypothesis that these first indications of cartilage degeneration were due to a transient rise in β-catenin in AC triggering cartilage catabolism and changes in the chondrocyte phenotype.
Abnormally regulated GSK3β has been associated with many pathological conditions like Alzheimer's disease, mood disorders, diabetes and cancer (7) . However, a direct link between GSK3β and the pathophysiology of OA has not yet been reported. Since in our experimental set-ups the GIN-induced effects reflect some of the pathological findings normally seen in osteoarthritic chondrocytes, we speculate that Gsk3β plays a role in the pathophysiology of this degenerative cartilage disease as well, most likely by regulating the levels of β-catenin. Whether pharmacological modulation of Gsk3β might represent a potential novel therapeutical approach for the management of OA remains to be elucidated. 
